For Immediate Release: September 16, 2015
David G. Orloff, MD, Senior Vice President, Medical and Regulatory Affairs Dies after a Prolonged Illness
Cincinnati, OH. (September 16, 2015) – It is with deep regret that Medpace announces the death of David G. Orloff. MD, Sunday, September 13, in New York after a prolonged illness. For many of our Sponsors who had not worked with Dr. Orloff, he was part of the fabric of Medpace life, contributing significantly on the Executive Committee and Medpace Board. His leadership in the area of metabolic disorders positioned Medpace as an industry leader in this therapeutic area.
More importantly David was a trusted advisor, colleague, and friend to many at Medpace as well as industry colleagues who worked with him on a daily basis.
At the family’s request, in lieu of sending flowers, donations may be made to organizations that he valued such as WAMU 88.5 or NYU Medical School.
How to Donate:
NYU Click on “Make a Gift” to donate in honor of Dr. David G. Orloff.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.